Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONOS-3: Copanlisib + rituximab vs placebo + rituximab in relapsed indolent B-cell non-Hodgkin lymphoma
jRCT2080223649Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in mature B-cell lymphoma, follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 3 more comparing Copanlisib + rituximab with Placebo + rituximab (2 arms). Started Sep 2017; status: completed.
02
Drugs
copanlisib
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on jRCT2080223649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223649.